Florida Chapter
American College of Surgeons




Genomic Assays for Personalizing Cancer Care

Warning message

Mean Menu style requires jQuery library version 1.7 or higher, but you have opted to provide your own library. Please ensure you have the proper version of jQuery included. (note: this is not an error)
Register

CONTINUING MEDICAL EDUCATION CREDIT INFORMATION

Accreditation
The American College of Surgeons is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA PRA Category 1 CreditsTM
The American College of Surgeons designates this enduring material for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Of the AMA PRA Category 1 CreditsTM listed above, a maximum of 1 credit meets the requirements for Self-Assessment.

 

 

 

PROGRAM OBJECTIVES
This activity is designed for surgeons. Upon completion of this course, participants should be able to:

  1. Identify the most clinical relevant genomic targets and when they should be utilized in lung adenocarcinoma.
  2. Discuss strengths and limitations of currently available breast cancer-specific genomic assays.
  3. Appraise the latest molecular characterization of colorectal cancer and associated treatments.

ORIGINAL DATE OF RELEASE
June 25, 2018

DISCLOSURE POLICY
In accordance with the ACCME Accreditation Criteria, the American College of Surgeons must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any commercial interest. Therefore, it is mandatory that both the program planning committee and speakers complete disclosure forms. Individuals were required to disclosure all commercial relationships prior to their participation in the activity. The ACCME defines a ‘commercial interest’ as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients”. It does not consider providers of clinical service directly to patients to be commercial interests. The ACCME considers “relevant” financial relationships as financial transactions (in any amount) that may create a conflict of interest and occur within the 12 months preceding the time that the individual is being asked to assume a role controlling content of the educational activity.

The ACCME also requires that ACS manage any reported conflict and eliminate the potential for bias. The planning committee members and speakers were contacted and the conflicts listed below have been managed to our satisfaction. However, if you perceive a bias, please advise us of the circumstances on the session evaluation form.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the educational activity.

SPEAKERS / MODERATORS/ CHAIRS / DISCUSSANTS NOTHING TO DISCLOSE DISCLOSURE
(As it pertains to the content of the presentation)
Bharti Jasra, MBBS, FACS X
Michael R. Shafique, MD X
Jason Starr, DO Celgene, Honorarium/Advisory Board
Christine Laronga, MD, FACS Genomic Health, Honoraria/Speakers Bureau
Up-to-Date, Royalties/Editor (sections on DCIS, Breast Cysts)
PLANNING COMMITTEE NOTHING TO DISCLOSE DISCLOSURE
(All commercial relationships)
All Members X
Register

Publication Date: 
Thursday, June 21, 2018 - 9:15am
Category: